Lupin receives FDA approval for Budesonide Inhalation Suspension, 0.5 mg/2 ml

Deepthi | Myequity news | Date : 13-11-2018 12:20:00 IST

Lupin received approval for its Budesonide Inhalation Suspension, 0.5 mg/2 ml Single-Dose Ampules from the United States Food and Drug Administration (FDA) to market a generic version of AstraZeneca Pharmaceuticals LP’s (AstraZeneca) Pulmicort Respules Inhalation Suspension, 0.5 mg/2 ml.

Lupin’s Budesonide Inhalation Suspension, 0.5 mg/2 ml Single-Dose Ampules is the generic version of AstraZeneca’s Pulmicort Respules Inhalation Suspension, 0.5 mg/2 ml. It is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age.


Budesonide Inhalation Suspension, 0.5 mg/2 ml Single-Dose Ampules had annual sales of approximately USD $474.5 million in the US (IQVIA MAT September 2018).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.


More from Myequity